ArticleArthritis research & therapy2018
Cytokine profiling in active and quiescent SLE reveals distinct patient subpopulations.
Article in Arthritis research & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Unravelling the connection between interferons and systemic lupus erythematosus: a systematic review and meta-analysis.BMC medicine · 2025Pooled it
- A Comprehensive Review of Biological Agents for Lupus: Beyond Single Target.Frontiers in immunology · 2020Pooled it
- Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways.Lupus science & medicine · 2020Trial
- Single-cell Unperturbed Activation Profiling by mass cytometry capturesFrontiers in immunology · 2026Article
- Plasma catecholamine metabolites are associated with disease activity and pathophysiological features in systemic lupus erythematosus using targeted LC-MS/MS.Scientific reports · 2025Article
- Serum untargeted metabolomics alterations in systemic lupus erythematosus patients with elevated serum ferritin.Scientific reports · 2025Article
- Immune cell aberrations in Systemic Lupus Erythematosus: navigating the targeted therapies toward precision management.Cellular & molecular biology letters · 2025Review
- Scavenger receptors: key players in the immunological puzzle of lupus.Frontiers in lupus · 2025Article
- Machine learning identifies cytokine signatures of disease severity and autoantibody profiles in systemic lupus erythematosus - a pilot study.Scientific reports · 2024Article
- High Interleukin 21 Levels in Patients with Systemic Lupus Erythematosus: Association with Clinical Variables and rs2221903 Polymorphism.Journal of clinical medicine · 2024Article
- SLE serum induces altered goblet cell differentiation and leakiness in human intestinal organoids.EMBO molecular medicine · 2024Article
- Proteomic analyses reveal cystatin c is a promising biomarker for evaluation of systemic lupus erythematosus.Clinical proteomics · 2023Article
- Immunoprofiling of cytokines, chemokines, and growth factors in female patients with systemic lupus erythematosus- a pilot study.BMC immunology · 2023Article
- Article
- Application of Machine Learning Models in Systemic Lupus Erythematosus.International journal of molecular sciences · 2023Review
- Complement as a Biomarker for Systemic Lupus Erythematosus.Biomolecules · 2023Review
- AlteredDiagnostics (Basel, Switzerland) · 2022Article
- Identification of genomic determinants contributing to cytokine release in immunotherapies and human diseases.Journal of translational medicine · 2022Article
- The promise of precision medicine in rheumatology.Nature medicine · 2022Review
- Effect of add-on hydroxychloroquine therapy on serum proinflammatory cytokine levels in patients with systemic lupus erythematosus.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPatients with SLE display marked clinical and immunlogical heterogeneity. The purpose of the study was to investigate patterns of serum cytokines in patients with active and stable systemic lupus erythematosus (SLE) and to determine how they relate to clinical phenotype.
methodsSerum levels of 10 cytokines were measured retrospectively in a cohort of patients with SLE and in healthy controls using a high-sensitivity multiplex bead array. Disease activity was determined using the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) and British Isles Lupus Assessment Group (BILAG-2004) indices. Logistic regression models were used to determine the association between cytokine levels and active SLE. Principal component analysis (PCA) and cluster analysis was then used to identify subgroups of patients on the basis of cytokine levels.
resultsSerum chemokine (C-X-C motif) ligand 10 (CXCL10) and CXCL13 were significantly higher in patients with SLE compared to healthy controls. Two cytokines (pentraxin-related protein (PTX3) and CXCL10) were significantly higher in patients with active disease after adjustment for potential confounding factors. Measurement of four cytokines (CXCL10, IL-10, IL-21 and PTX3) significantly improved the performance of a model to identify patients with clinically active disease. Cluster analysis revealed that the patients formed 3 distinct groups, characterised by higher levels of interferon alpha (IFNα) and B lymphocyte stimulator (BLyS) (group 1), increased CXCL10 and CXCL13 (group 2) or low levels of cytokines (group 3). Group 2 had significantly lower serum complement and higher anti-double-stranded DNA antibodies and increased prevalence of inflammatory arthritis.
conclusionsMultiplex analysis has identified a serum cytokine signature for active SLE. Within the SLE population distinct cytokine subgroups were identified, with differing clinical and immunological phenotypes that appeared stable over time. Assessment of cytokine profiles may reveal unique insights into disease heterogeneity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.